Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
A milestone for Tmalin
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
US shutdown freezes new drug applications
Key FDA decisions are expected to face delays.
Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
